Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742643 | 0.83 | NPSR1 (0.51) | ENPP2LPLLIPGCA2TRPV1 | |
| SCHEMBL134473 | 0.80 | ALDH1A1 (0.55) | ENPP2LPLLIPGCA2TRPV1 | |
| SCHEMBL1081442 | 0.79 | CA2 (0.43) | ENPP2LPLLIPGCA2TRPV1 | |
| SCHEMBL12302001 | 0.79 | ALDH1A1 (0.48) | HDAC4GRM1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4503118 | 0.79 | CA1 (0.47) | HDAC4CA2LIMK2HPGDALDH1A1 | |
| SCHEMBL25870881 | 0.77 | USP5 (0.50) | HDAC4LIMK2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13034674 | 0.77 | HDAC4 (0.49) | HDAC4CA2GRM1HPGDALDH1A1 | |
| SCHEMBL394512 | 0.76 | HSD11B1 (0.53) | HDAC4LIMK2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL2701722 | 0.76 | ERN1 (0.53) | CA2TRPV1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25041339 | 0.74 | LIMK2 (0.43) | HDAC4LIMK2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | HDAC4 4087/4885ENPP2 1916/4885LPL 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.